Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine: Randomized study in toddlers in Taiwan

Li Min Huang, Tzou Yien Lin, Cheng Hsun Chiu, Nan Chang Chiu, Po Yen Chen, Shu Jen Yeh, Mark Boaz, Yanee Hutagalung, Alain Bouckenooghe, Emmanuel Feroldi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Japanese encephalitis (JE) is the most important cause of viral encephalitis in Asia. Methods: In this randomized, open-label, multicenter trial in 550 children aged 12 to 18 months in Taiwan, children received one dose of JE-CV and one dose of MMR vaccine. Vaccines were either administered separately 6 weeks apart (Groups 'JE-CV' and 'MMR', named after which vaccine was given first), or concomitantly (Group 'Co-Ad'). JE neutralizing antibody titers were assessed using PRNT50. MMR antibody levels were determined by ELISA. Results: All groups had low seroprotection/seropositivity rates (<10%) before vaccination for all antigens. Forty two days after vaccination, on either Study Day 42 or 84, seroconversion rates for all antigens were high in all groups, irrespective of the order of vaccinations. Seroconversion for JE ranged from 96.9% in Group Co-Ad on D42 to 100% in Group MMR. Non-inferiority was demonstrated for all analyses as the lower bound of the 95% CI of the difference in seroconversion rates between groups was above the pre-defined limit of -10.0%. The immune responses remained high for all antigens and well above the level of protection 12 months after vaccination in all groups. There were no safety concerns. Conclusions: JE-CV is safe and induces a strong protective immune response which persists over 1 year when co-administered with MMR vaccine.

Original languageEnglish
Pages (from-to)5363-5369
Number of pages7
JournalVaccine
Volume32
Issue number41
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Japanese Encephalitis Virus
Measles-Mumps-Rubella Vaccine
toddlers
encephalitis
Japanese Encephalitis
Taiwan
Vaccination
Vaccines
vaccines
viruses
Mumps
Measles
Antigens
seroconversion
vaccination
Viral Encephalitis
Japanese Encephalitis Viruses
Rubella
antigens
Neutralizing Antibodies

Keywords

  • Children
  • Immunogenicity
  • Japanese encephalitis (JE) vaccine
  • MMR
  • Safety

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine
  • Medicine(all)

Cite this

Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine : Randomized study in toddlers in Taiwan. / Huang, Li Min; Lin, Tzou Yien; Chiu, Cheng Hsun; Chiu, Nan Chang; Chen, Po Yen; Yeh, Shu Jen; Boaz, Mark; Hutagalung, Yanee; Bouckenooghe, Alain; Feroldi, Emmanuel.

In: Vaccine, Vol. 32, No. 41, 2014, p. 5363-5369.

Research output: Contribution to journalArticle

Huang, Li Min ; Lin, Tzou Yien ; Chiu, Cheng Hsun ; Chiu, Nan Chang ; Chen, Po Yen ; Yeh, Shu Jen ; Boaz, Mark ; Hutagalung, Yanee ; Bouckenooghe, Alain ; Feroldi, Emmanuel. / Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine : Randomized study in toddlers in Taiwan. In: Vaccine. 2014 ; Vol. 32, No. 41. pp. 5363-5369.
@article{401ef3e91a8149d1b77ac3212325de19,
title = "Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine: Randomized study in toddlers in Taiwan",
abstract = "Background: Japanese encephalitis (JE) is the most important cause of viral encephalitis in Asia. Methods: In this randomized, open-label, multicenter trial in 550 children aged 12 to 18 months in Taiwan, children received one dose of JE-CV and one dose of MMR vaccine. Vaccines were either administered separately 6 weeks apart (Groups 'JE-CV' and 'MMR', named after which vaccine was given first), or concomitantly (Group 'Co-Ad'). JE neutralizing antibody titers were assessed using PRNT50. MMR antibody levels were determined by ELISA. Results: All groups had low seroprotection/seropositivity rates (<10{\%}) before vaccination for all antigens. Forty two days after vaccination, on either Study Day 42 or 84, seroconversion rates for all antigens were high in all groups, irrespective of the order of vaccinations. Seroconversion for JE ranged from 96.9{\%} in Group Co-Ad on D42 to 100{\%} in Group MMR. Non-inferiority was demonstrated for all analyses as the lower bound of the 95{\%} CI of the difference in seroconversion rates between groups was above the pre-defined limit of -10.0{\%}. The immune responses remained high for all antigens and well above the level of protection 12 months after vaccination in all groups. There were no safety concerns. Conclusions: JE-CV is safe and induces a strong protective immune response which persists over 1 year when co-administered with MMR vaccine.",
keywords = "Children, Immunogenicity, Japanese encephalitis (JE) vaccine, MMR, Safety",
author = "Huang, {Li Min} and Lin, {Tzou Yien} and Chiu, {Cheng Hsun} and Chiu, {Nan Chang} and Chen, {Po Yen} and Yeh, {Shu Jen} and Mark Boaz and Yanee Hutagalung and Alain Bouckenooghe and Emmanuel Feroldi",
year = "2014",
doi = "10.1016/j.vaccine.2014.02.085",
language = "English",
volume = "32",
pages = "5363--5369",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "41",

}

TY - JOUR

T1 - Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine

T2 - Randomized study in toddlers in Taiwan

AU - Huang, Li Min

AU - Lin, Tzou Yien

AU - Chiu, Cheng Hsun

AU - Chiu, Nan Chang

AU - Chen, Po Yen

AU - Yeh, Shu Jen

AU - Boaz, Mark

AU - Hutagalung, Yanee

AU - Bouckenooghe, Alain

AU - Feroldi, Emmanuel

PY - 2014

Y1 - 2014

N2 - Background: Japanese encephalitis (JE) is the most important cause of viral encephalitis in Asia. Methods: In this randomized, open-label, multicenter trial in 550 children aged 12 to 18 months in Taiwan, children received one dose of JE-CV and one dose of MMR vaccine. Vaccines were either administered separately 6 weeks apart (Groups 'JE-CV' and 'MMR', named after which vaccine was given first), or concomitantly (Group 'Co-Ad'). JE neutralizing antibody titers were assessed using PRNT50. MMR antibody levels were determined by ELISA. Results: All groups had low seroprotection/seropositivity rates (<10%) before vaccination for all antigens. Forty two days after vaccination, on either Study Day 42 or 84, seroconversion rates for all antigens were high in all groups, irrespective of the order of vaccinations. Seroconversion for JE ranged from 96.9% in Group Co-Ad on D42 to 100% in Group MMR. Non-inferiority was demonstrated for all analyses as the lower bound of the 95% CI of the difference in seroconversion rates between groups was above the pre-defined limit of -10.0%. The immune responses remained high for all antigens and well above the level of protection 12 months after vaccination in all groups. There were no safety concerns. Conclusions: JE-CV is safe and induces a strong protective immune response which persists over 1 year when co-administered with MMR vaccine.

AB - Background: Japanese encephalitis (JE) is the most important cause of viral encephalitis in Asia. Methods: In this randomized, open-label, multicenter trial in 550 children aged 12 to 18 months in Taiwan, children received one dose of JE-CV and one dose of MMR vaccine. Vaccines were either administered separately 6 weeks apart (Groups 'JE-CV' and 'MMR', named after which vaccine was given first), or concomitantly (Group 'Co-Ad'). JE neutralizing antibody titers were assessed using PRNT50. MMR antibody levels were determined by ELISA. Results: All groups had low seroprotection/seropositivity rates (<10%) before vaccination for all antigens. Forty two days after vaccination, on either Study Day 42 or 84, seroconversion rates for all antigens were high in all groups, irrespective of the order of vaccinations. Seroconversion for JE ranged from 96.9% in Group Co-Ad on D42 to 100% in Group MMR. Non-inferiority was demonstrated for all analyses as the lower bound of the 95% CI of the difference in seroconversion rates between groups was above the pre-defined limit of -10.0%. The immune responses remained high for all antigens and well above the level of protection 12 months after vaccination in all groups. There were no safety concerns. Conclusions: JE-CV is safe and induces a strong protective immune response which persists over 1 year when co-administered with MMR vaccine.

KW - Children

KW - Immunogenicity

KW - Japanese encephalitis (JE) vaccine

KW - MMR

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=84925884794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925884794&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2014.02.085

DO - 10.1016/j.vaccine.2014.02.085

M3 - Article

C2 - 24631095

AN - SCOPUS:84925884794

VL - 32

SP - 5363

EP - 5369

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 41

ER -